Understanding Inclusion and Exclusion Criteria in Clinical Trials
Eligibility criteria are important for any clinical trial protocol. While the criteria can look simple, they are important and should be applied in practice. These inclusion and exclusion criteria determine who is eligible to participate in a trial and who is not.
What Are Inclusion and Exclusion Criteria in Clinical Trials?
Inclusion and exclusion criteria in clinical trials are the requirement for participant participation in a clinical trial. The inclusion criteria are the characteristics, demographics, diagnosis, lab results, etc. that a prospective patient must have in order to qualify as a study participant. Exclusion criteria is on the opposite end, where those attributes disqualify them as a prospective participant. Even if the potential participant meets the inclusion criteria, any exclusion criteria would supersede and exclude them from participation. Exclusion criteria are the characteristics that disqualify them, even if every inclusion criterion is met.
As a simple example, a hypertension inclusion and exclusion criteria trial might look:
Inclusion: Adults aged 18–65; diagnosed with essential hypertension for at least 6 months; stable on current medication for 4 weeks.
Exclusion: History of secondary hypertension; current use of an investigational drug within 30 days; pregnancy or breastfeeding; severe renal impairment.
Together, these criteria define the study population the trial's results are meant to generalize to.
Why Eligibility Criteria Exist
Eligibility criteria aren't arbitrary and are established based on three interconnected purposes.
Scientific Validity
As clinical research and trials are designed to answer a specific question about a specific population, broadening the test population too much introduces variables that can obscure whether a treatment effect is real. By narrowing it appropriately, researchers are able to isolate the variable of interest.
Participant safety
The investigational product (IP) may not be safe or applicable for everyone. Exclusion criteria are often in place to protect people who could be harmed by the IP.
Regulatory and ethical integrity
Eligibility criteria must align with the protocol reviewed and approved by the Institutional Review Board (IRB). Any deviation from them is treated as a protocol deviation requiring documentation following ALCOA-C principles and, in many cases, reporting.
Common Categories of Eligibility Criteria
Every protocol is different but most eligibility criteria fall into a handful of recurring categories:
Demographic factors — age range, sex, sometimes race/ethnicity when relevant to disease prevalence or drug metabolism
Diagnostic criteria — confirmed diagnosis of the condition under study, often requiring specific diagnostic tests or documented history
Disease severity or stage — mild, moderate, or severe disease; early- vs. late-stage classifications
Prior and concurrent treatment history — washout periods for prior medications, prohibited concomitant medications, prior trial participation limits
Comorbidities — conditions that could confound results or pose safety risks
Laboratory and vital sign thresholds — specific ranges for liver enzymes, kidney function, blood counts, blood pressure, and similar values
Reproductive status — pregnancy, breastfeeding, and contraception requirements, common in trials involving drugs with unknown reproductive effects
Cognitive and consent capacity — the ability to understand and provide informed consent, particularly relevant in trials involving cognitive impairment
Understanding these categories helps site staff anticipate what documentation will be needed at screening. This should be put together before a potential participant is in the building.
How Site Staff Apply Criteria in Practice
For clinical research coordinators (CRCs), eligibility criteria are the basis for a working document referenced at every step of the screening process.
Pre-screening
In order to save both staff and patients time, many sites review the electronic health record or existing patient panel against key inclusion/exclusion points before scheduling a screening visit,
Screening visit documentation
Every criterion needs a source document that supports it. This can be a lab value, a diagnosis note, a medication list. This is where the principles behind ALCOA-C (Attributable, Legible, Contemporaneous, Original, Accurate, and Complete) become directly relevant. Determinations of a potential participant's eligibility are only as strong as the documentation behind them.
Eligibility review and sign-off
Most protocols require the Principal Investigator, or a qualified sub-investigator, to formally confirm and sign off on eligibility before enrollment. This step should be taken with care as it is often scrutinized closely during monitoring visits and audits.
Screen failure tracking
Not every prospective participant will qualify, and that's expected. Sponsors and IRBs generally want screen failure rates and reasons tracked, both to assess protocol feasibility and to flag criteria that may be unintentionally too restrictive.
Common Pitfalls Sites Run Into
A few issues tend to surface repeatedly, even at experienced sites:
Overlooking a criterion buried in an amendment. Protocol amendments often adjust eligibility criteria mid-study. Sites that don't systematically update their screening checklists risk enrolling participants against outdated criteria.
Inconsistent interpretation among staff. Criteria that involve clinical judgment (e.g., "stable disease") can be interpreted differently by different team members without a shared, documented standard.
Treating eligibility as a one-time check. Some criteria, like concomitant medication restrictions, must be reconfirmed at multiple points in the study, not just at baseline.
Under-documenting the "why" behind exclusions. When a participant is excluded, the specific reason should be clearly recorded, both for sponsor reporting and for the site's own feasibility assessments on future studies.
Why This Matters Beyond Compliance
Proper management of eligibility criteria provides downstream benefits to clinical trial sites. They help improve the screening process to reduce time wasted for staff and prospective patients, it protects the site's relationship with the sponsor or site management organization (SMO), and it establishes a track record to make the site more attractive to future studies. Sites that build clear, consistent, well-documented screening processes around those criteria are able to be successful both for their sponsors and for the patients they're trying to help.
Note: This article is intended as a general educational overview. Specific eligibility requirements, documentation standards, and regulatory expectations vary by protocol, sponsor, and jurisdiction — always defer to the current protocol and applicable regulatory guidance.
Comments